Navigation Links
Sirion Therapeutics Supports Ophthalmic Education
Date:9/28/2007

- Company Provides Unrestricted Educational Grants to Support the 25th

Biennial Cornea Research Conference and the Inaugural DIRECT Dry AMD

Meeting -

TAMPA, Fla., Sept. 28 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced its support of the advancement of ocular innovation through its contributions of unrestricted educational grants to two upcoming ophthalmology conferences.

The first conference is Harvard University's Schepens Eye Research Institute's 25th Biennial Cornea Research Conference, taking place October 12 and 13, 2007 in Boston, MA. Schepens is the largest independent eye research institute in the nation, and an affiliate of Harvard Medical School. For additional information on this meeting, please visit their website at http://www.schepens.harvard.edu/cornea07.htm.

The second contribution will benefit the Duke University School of Medicine's Inaugural DIRECT Dry AMD Meeting, taking place October 25-27, 2007 in Durham, NC. This conference will update attendees with the latest information on Dry Age-related Macular Degeneration (AMD). For additional information on this meeting, please visit their website at http://www.directamd.com.

"Both of these conferences play a vital role in the awareness and advancement of research in ophthalmology," said Barry Butler, Sirion's President and Chief Executive Officer. "We appreciate the opportunity to support these institutions in advancing the treatment of ophthalmic disease."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four late-stage opportunities: ganciclovir, a topical antiviral for herpetic keratitis which is awaiting an NDA filing in early 2008; difluprednate, a potent topical steroid in Phase III development for post-operative inflammation and uveitis; cyclosporine, a topical immunomodulator in Phase III testing for dry eye and fenretinide, a first-in-class oral vitamin A binding protein antagonist in Phase II development for geographic atrophy associated with dry AMD. For more information regarding Sirion, please visit Sirion's website at http://www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. CDW buyer supports Berbee growth plans
3. Tech center supports energy-saving device for heat-treating plants
4. Inacom Supports Blackhawk Technology Mentor Program
5. Computer Card Supports Solo Doctor
6. Federal Funding Supports Small Business Innovation
7. Doyle urges support of higher education spending
8. Jump starting technology education
9. Stem cell and regenerative medicine center to aid education and commerce
10. Education is fundamental to Milwaukees growth
11. New book touts educational power of computer games
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/4/2016)... ... December 02, 2016 , ... ... and -operated small businesses in federally funded research and development is welcome news ... for optics and photonics . , As part of the National Defense Authorization ...
(Date:12/4/2016)... and CAMBRIDGE, Mass. and ... Dec. 4, 2016 SystemOne, a company ... software platforms for the developing world, and Daktari ... a reality with its portable and ultrasensitive immunoassay-based ... a development and license agreement to integrate Daktari,s ...
(Date:12/2/2016)... NORWALK, Conn. , Dec. 2, 2016  The ... research presentations from the MMRF CoMMpass Study SM —the ... and accelerating precision medicine in multiple myeloma—will be presented ... (ASH) Annual Meeting & Exposition in San ... are helping to optimize treatment strategies, as well as ...
Breaking Biology Technology:
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
Breaking Biology News(10 mins):